Showcasing the Exciting Profiles of ADCs Targeting DLL3 & Evaluating Promising ADC Development Against Lower–Expressed Tumor Targets

• Explaining the journey of ADC development against low-expressed tumor targets: from previously off limits to emerging advantages against modalities like TCEs
• Diving into a case study of ADC development and profiles against DLL3
• Exploring wider context of ADC successes and development in antigen-low populations in solid tumors